Jonathan Knowles has been very active in promoting Personalized Medicine in both academia and the pharmaceutical industry for several decades. He was Head of Group Research and Member of the Executive Committee at Roche up to the end of 2009. He was a member of the Genentech Board for 12 years and a member of the Chugai Board for 7 years. Under his leadership, the Roche group developed and implemented a strategy of highly effective therapies based on personalized healthcare. He was for 5 years the Chairman of the Hever Group and the Research Directors’ Group of EFPIA and was the founding chairman of the Board of the Innovative Medicines Initiative, a unique public private partnership with a budget of over 5 Billion Euros. Jonathan Knowles held a Distinguished Professorship in Personalised medicine at FIMM (Institute for Molecular Medicine Finland) at the University of Helsinki 2010-201. He was appointed as Executive chairman of Immunocore Ltd. and Adaptimmune Ltd, two leading UK Cancer Immunotherapy Companies since 2013 and serves on the boards of a number of Biotech companies.